Next-generation checkpoint development surges as rare wins overshadow setbacks
Companies look to overcome challenges in next-generation checkpoints with new targets and modalities
Companies look to overcome challenges in next-generation checkpoints with new targets and modalities.
Though the failure rate of next-generation checkpoints has far out-stripped that of the rare successes, companies have not been scared away from the search for the next blockbuster, or for a way to finally cut back checkpoint resistance.
New additions to the checkpoint pipeline have outpaced terminations as the number of programs against next-generation T cell checkpoints expands each year. The candidate collection is also beginning to look much more diverse as companies turn to new targets, new mechanisms and new modalities in the search for a safe and effective agent.
After PD-1 inhibitor Keytruda pembrolizumab was approved in 2015, the industry flocked to next-generation checkpoint targets hoping to replicate, or even improve